Q2 results Prevas reported a weaker-than-expected Q2'25, with sales of SEK 409m, up 3% y-o-y (4% bel...
Q2 results Q2 sales were SEK 3,601m (+1% vs. ABGSCe 3,550m), -13% y-o-y.
Redeye provides and initial comment on the Q2 2025 report from Safeture, which showed negative ARR g...
Redeye comments on Arise’s Q2 report, which saw higher production than expected, driving the segment...
Q2 details Infrea delivered a mixed report with higher sales and lower adj.
Following Telia’s bid for Bredband2 at SEK3.25 per share, InfraCom has agreed to tender its shares.
Q2 details Sales were 2% above our expectations, with 7% organic sales growth (ABGSCe +4%), which in...
Q2 results Orders were up 12% y-o-y and 3% below our estimate.
Q2 figures in line with pre-announcement The Q2 figures were in line with the profit warning issued ...
Consti's net sales in Q2 amounted to EUR 84.8m, surpassing our estimate (Evli est.
Tiratricol now has US FDA Breakthrough Therapy Designation for MCT8 deficiency, which is essential f...
Dynavox delivered another impressive report, with sales 8% above our forecast and 3% ahead of consen...
Redeye comments on the takeover offer on Bredband2 from Telia Company.
Q2 outcome Sales was SEK 2,395m (+2% vs. ABG 2,345m, +2% vs.
Offer at SEK 3.25/share In a move that was not too unexpected, Telia made a cash offer of SEK 3.
